CEL-SCI CORP (CVM) Stock Price & Overview
NYSEARCA:CVM • US1508377066
The current stock price of CVM is 3.87 USD. Today CVM is down by -1.78%. In the past month the price decreased by -22.6%. In the past year, price decreased by -57.57%.
CVM Key Statistics
- Market Cap
- 32.74M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
CVM Stock Performance
CVM Stock Chart
CVM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CVM. When comparing the yearly performance of all stocks, CVM is a bad performer in the overall market: 94.64% of all stocks are doing better.
CVM Earnings
CVM Forecast & Estimates
5 analysts have analysed CVM and the average price target is 25.5 USD. This implies a price increase of 558.91% is expected in the next year compared to the current price of 3.87.
CVM Groups
Sector & Classification
CVM Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CVM Ownership
CVM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.33 | 402.17B | ||
| AMGN | AMGEN INC | 16.52 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.59 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.77 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.37 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.71 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.72 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 341.2 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CVM
Company Profile
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Company Info
IPO: 1983-12-08
CEL-SCI CORP
Suite 802, 8229 Boone Blvd .
Vienna VIRGINIA 22182 US
CEO: Geert Kersten
Employees: 0
Phone: 17035069460
CEL-SCI CORP / CVM FAQ
Can you describe the business of CEL-SCI CORP?
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
What is the current price of CVM stock?
The current stock price of CVM is 3.87 USD. The price decreased by -1.78% in the last trading session.
What is the dividend status of CEL-SCI CORP?
CVM does not pay a dividend.
What is the ChartMill technical and fundamental rating of CVM stock?
CVM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the analyst forecast for CVM stock?
5 analysts have analysed CVM and the average price target is 25.5 USD. This implies a price increase of 558.91% is expected in the next year compared to the current price of 3.87.
How many employees does CEL-SCI CORP have?
CEL-SCI CORP (CVM) currently has 0 employees.